🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ASPET’s Editorial Fellowship Program is accepting applications for its 2025 class. Fellows will learn important elements of the editorial process, including all aspects of the submission process, peer review, and editorial decisions. Apply by Dec 11: ow.ly/4IMN50U7SMT.

Prostaglandin DP2 receptors are involved in type 2 inflammation occurring in many allergic conditions. Researchers from Marburg show that the prostaglandin precursor arachidonic acid can directly activate DP2 but not DP1 receptors. Read more here: ow.ly/ocez50UgVwq

Investigators from Thomas Jefferson University review naturally occurring mutations of a G protein alpha subunit are constitutively active and how their aberrant signaling can contribute to cancer. Such mutations are prevalent in several cancers. Read more here: ow.ly/8iRQ50UgVJP

The December 2024 Highlighted Trainee Author for MolPharm is Elijah Ullman, a recent PhD graduate of Emory School of Medicine. He believes his research will advance the pharmacological toolset and knowledge base for allosteric modulation. Read his work here: doi.org/10.1124/molpha…

Viennese investigators identified novel inhibitors of creatine transporter-1 from the guanidino-carboxylic acid family. They provide proof-of-principle for inhibiting this transporter, a proposed anti-cancer drug target. Read the article here: ow.ly/YoZL50UmqPi

Researchers from Emory School of Medicine show that EU1622-240 increases open probability and agonist potency while reducing single-channel conductance and prolonging deactivation by allosterically promoting binding of glycine or glutamate as co-agonist. Read more: ow.ly/4Fa250Ums4u

Nav1.8 is a target for novel analgesics, and candidate drugs acting on Nav1.8 are in clinical trials. Harvard investigators act as state-dependent inhibitors of this channel whereby inhibition is relieved by depolarization. Read more here: ow.ly/tPUU50Umsgo

Big news! ASPET's journals are now live on the Elsevier platform! This partnership will: 🔬 Expand the journals’ global reach 🔬 Increase the usage of innovative technologies 🔬 Provide more opportunities to share cutting-edge science Learn more: aspet.org/aspet/journals

The January 2025 Highlighted Trainee Author for Mol Pharm is Gavin Traber, a recent PhD graduate of UCDavisMedSchool. He hopes his research will provide a step forward in the use of microRNAs and other non-coding RNAs as novel therapeutic strategies. Read here: ow.ly/ZiFM50UMxTI

An #interactome study from @hopkinsmedicine identifies 14-3-3 proteins (6 of 7 isoforms) as restricting access of the beta2 adrenergic receptor to its signaling partners, thereby being becoming negative regulators of receptor function. Read the article: doi.org/10.1124/molpha…

Researchers from UCSF School of Medicine identified the N-terminal domain of GRK2/3 to be required for the full agonist selectivity of receptor-GRK2 interaction and show that it is also required for GRK2 to promote receptor endocytosis after it is bound. Read here: doi.org/10.1124/molpha…

Researchers from Collaborations Pharmaceuticals used machine learning models to identify the tyrosine kinase inhibitor lapatinib as antagonist at chemokine receptors 3, 4 and 5, highlighting the role of such approaches for drug discovery. Read here: doi.org/10.1016/j.molp…

Anthony Garcia, a PhD Candidate at Umich Pharmacology, is the February Highlighted Trainee Author. He hopes his research will be helpful in dissecting the role of protein chaperones as a potential therapeutic target for protein misfolding diseases: doi.org/10.1016/j.molp….

Lily Jan, PhD, from @ucsf_bms_jc reviews recent structural evidence, how cells can sense voltage are involved in the gating of voltage-gated ion channels as well as the sperm-specific Na+/H+-exchanger or voltage-sensing phosphatases. Read the article here: doi.org/10.1016/j.molp…

Bertil Hille from @uwmedicine discusses the history of the action potential, the quintessential electrical message of nerves. He highlights the role of choosing informative preparations and experimental genius. Read the research: doi.org/10.1016/j.molp…

Victoria Saca, a 5th year PhD student at @rockefelleruniv, is a Highlighted Trainee Author for Molecular Pharmacology. She hopes that her research will help expand the use of PROTAC technology to target GPCRs and other membrane proteins. Read the article: doi.org/10.1016/j.molp….

Joy Li, a Postdoctoral Scholar at UCSF School of Medicine, is the April 2025 Highlighted for MolPharm. Her research is part of an ongoing body of work to understand how different drugs exert selective effects on cells and organisms: doi.org/10.1124/molpha… #GPCR #endocytosis #cellbiology

Researchers from Davis and Irvine report that the alleged binding site of NS309 is a crystallization artifact and identify the true binding site. NS309 appears to increase the open probability of the inner hydrophobic gate of KCa3.1. Read the article here: doi.org/10.1016/j.molp…

Keren Chen, a student at University of British Columbia, is the May 2025 Highlighted Trainee Author for MolPharm. Her published research focuses on understanding neurodegenerative diseases, which are conditions that cause the brain and nervous system to wear down. 🔗 Read here: doi.org/10.1016/j.molp….

Based on the potency of nicotinic receptor activation by nicotine and on its ability to chaperone such receptors, investigators from Caltech developed an app that allows to simulate early steps in the development of nicotine dependence. Read the research: doi.org/10.1016/j.molp…